Gastroenterology news

High loperamide doses linked to serious cardiac reactions

High loperamide doses linked to serious cardiac reactions

Cardiac events including QT prolongation, torsades...

NICE approves first treatment for IBS with diarrhoea

NICE approves first treatment for IBS with diarrhoea

Eluxadoline (Truberzi) can now be prescribed routinely...

NICE approves alternative biologic for Crohn's disease

NICE approves alternative biologic for Crohn's disease

Patients with moderate to severe Crohn's disease should...

Eluxadoline: first treatment option for IBS patients with diarrhoea

Eluxadoline: first treatment option for IBS patients with diarrhoea

Truberzi (eluxadoline) is a new orally administered...

Cardiac warning for anticholinergic injection

Cardiac warning for anticholinergic injection

Hyoscine butylbromide (Buscopan) injection should be...

New biologic option for Crohn's disease

New biologic option for Crohn's disease

Patients with moderately to severely active Crohn's...

Summaries of NICE bowel disease guidance published by MIMS

Summaries of NICE bowel disease guidance published by MIMS

GPs treating patients with inflammatory bowel disease...

Movicol now available in ready-to-use sachets
Ferric maltol: new iron therapy for patients with inflammatory bowel disease

Ferric maltol: new iron therapy for patients with inflammatory bowel disease

Feraccru (ferric maltol) is licensed for the treatment...

Updated MIMS summary of H. pylori treatment regimens

Updated MIMS summary of H. pylori treatment regimens

The popular quick-reference MIMS summary of NICE guidance...

Proton pump inhibitors associated with low risk of cutaneous lupus

Proton pump inhibitors associated with low risk of cutaneous lupus

Proton pump inhibitors (PPIs) are associated with very...

Naloxone derivative launched for opioid-induced constipation

Naloxone derivative launched for opioid-induced constipation

Naloxegol (Moventig) provides a new option for the...

NICE approves vedolizumab for Crohn's disease

NICE approves vedolizumab for Crohn's disease

The integrin inhibitor vedolizumab (Entyvio) has been...

New constipation treatment receives NICE approval

New constipation treatment receives NICE approval

The constipation treatment naloxegol (Moventig) will...

Women-only constipation treatment now licensed in men

Women-only constipation treatment now licensed in men

Prescribers can now consider the 5HT4 agonist prucalopride...

Ulcerative colitis treatment recommended by NICE

Ulcerative colitis treatment recommended by NICE

Vedolizumab (Entyvio) has been accepted by NICE for...

NICE recommends drug to prevent episodes of hepatic encephalopathy

NICE recommends drug to prevent episodes of hepatic encephalopathy

Rifaximin (Targaxan) has been accepted by NICE for...

Creon 40,000 (pancreatin) unavailable

Creon 40,000 (pancreatin) unavailable

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases